# US 2004/0072747 A1 · Novel member of the epha receptor family

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072747 A1
- Document ID: US20040072747A1
- Status: Published application
- Kind: A1
- Application number: 10/333,789
- Filed: 2003-01-24
- Published: 2004-04-15
- Earliest claimed: 2000-07-26
- Assignees: Merck Patent GmbH
- Inventors: Bjoern Hock; Klaus Duecker
- Web page: https://patentgrep.com/patent/US20040072747A1

## CPC

- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

EphA9 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing EphA9 polypeptides and polynucleotides in diagnostic assays.

## Claims

### Claim 1

A polypeptide selected from one of the groups consisting of:
(a) a polypeptide encoded by a polynucleotide comprising thesequence of SEQ ID NO:1 and/or SEQ ID NO:3 and/or SEQ ID NO:5 and/or SEQ ID NO:7;
(b) a polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8;
c) a polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8; and
d) the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8 and
(e) fragments and variants of such polypeptides in (a) to (d).

### Claim 2 (depends on 1)

The polypeptide as claimed in claim 1 comprising the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8.

### Claim 3 (depends on 1)

The polypeptide as claimed in claim 1 which is the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8.

### Claim 4

An polynucleotide selected from one of the groups consisting of:
(a) a polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3 and/or SEQ ID NO:5 and/or SEQ ID NO:7;
(b) a polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3 and/or SEQ ID NO:5 and/or SEQ ID NO:7;
(c) a polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8;
(d) a polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8;
(e) an polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides;
(f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);
or a polynucleotide sequence complementary to said polynucleotide
and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

### Claim 5 (depends on 4)

A polynucleotide as claimed in claim 4 selected from the group consisting of:
(a) a polynucleotide comprising the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3 and/or SEQ ID NO:5 and/or SEQ ID NO:7;
(b) the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3 and/or SEQ ID NO:5 and/or SEQ ID NO:7;
(c) a polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8; and
(d) a polynucleotide encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4 and/or SEQ ID NO:6 and/or SEQ ID NO:8.

### Claim 6 (depends on 1)

An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.

### Claim 7 (depends on 1, 6)

A recombinant host cell comprising the expression vector of claim 6 or a membrane thereof expressing the polypeptide of claim 1.

### Claim 8 (depends on 1, 7)

A process for producing a polypeptide of claim 1 comprising the step of culturing a host cell as defined in claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

### Claim 9 (depends on 1)

A fusion protein consisting of the Immunoglobulin Fc-region and any one polypeptide of claim 1.

### Claim 10 (depends on 1, 2, 3)

An antibody immunospecific for the polypeptide of any one of claims 1 to 3.

### Claim 11 (depends on 1)

A method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide of claim 1 comprising a method selected from the group consisting of:
(a) measuring or, detecting, quantitatively or qualitatively, the binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;
(b) measuring the competition of binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof in the presence of a labeled competitior;
(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes expressing the polypeptide;
(d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; or
(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using for instance, an ELISA assay, and
(f) producing said compound according to biotechnological or chemical standard techniques.
